Afatinib (Giotrif®)

Assessment Status Rapid Review Complete
Drug Afatinib
Brand Giotrif®
Indication As monotherapy is indicated for the treatment of Epidermal Growth Factor Receptor (EGFR) TKI-naïve adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating EGFR mutation(s).
Assessment Process
Rapid review commissioned 01/10/2013
Rapid review completed 13/10/2013
Rapid review outcome Full HTA not recommended